Friday, January 30, 2026

Pentagon on South Korea’s Impeachment Drama: Tensions Rise, But U.S. Support Remains Strong

The U.S. Defense Department expressed hope that no parties exploit South Korea's political turmoil, affirming ongoing cooperation with Seoul.

Hanwha Achieves Top CDP Climate Rating, Upgraded to Leadership A

Hanwha Group achieved the highest Leadership A rating in the 2024 Climate Change Response Assessment by CDP, highlighting its climate initiatives.

North Korea’s Shift to ‘Two-State’ Theory: What It Means for South-North Relations?

Unification Minister Chung Dong-young highlights North Korea's shift to a two-state theory in inter-Korean relations since 2017.

Tag: obesity treatment

North KoreaKoreaKimMilitarySouth KoreaAImarketrelationsInternational

Novo Nordisk’s Oral Wegovy Tops 3,000 Prescriptions in Its First Week—A Challenge to Injectable GLP-1s

Novo Nordisk's Wegovy oral treatment exceeds 3,000 prescriptions in its debut week, signaling a shift towards oral obesity medications.

Weight-Loss Drugs Could Cut Airline Fuel Bills by $580 Million—An Unexpected Win for U.S. Carriers

The obesity treatment market is growing, helping U.S. airlines save on fuel costs due to decreased passenger weight.

Patches, Implants, and Oral Films… The Drug-Delivery Format Battle After Oral Wegovy

Oral Wegovy's launch is transforming obesity treatment, focusing on user-friendly delivery methods and enhancing patient adherence.

Is RPG-102 the Future of Obesity Treatment? Discover the Breakthrough Oral Solution!

ProGen and Rani Therapeutics initiate a Phase 1 trial for RPG-102, an oral obesity treatment, aiming for effective weight loss with weekly dosing.

New Obesity Pill Could End Wegovy’s Reign, Offering Faster and Safer Results

Ildong's ID110521156 shows promise as an affordable GLP-1 obesity drug with fewer side effects, aiming to transform the treatment landscape.

Wegovy Gets Stronger: New Dose Promises Even More Weight Loss

Novo Nordisk's new high-dose Wegovy aims to enhance obesity treatment, with promising trial results and a strategic EU rollout planned.

As Wegovy and Mounjaro Soar, Korean Biotechs Seek a Slice of the Obesity Drug Market

South Korean firms are innovating in the GLP-1 obesity treatment market, developing unique drugs to compete with industry leaders.

New Obesity Drug Shows Big Promise — and It’s Not from Eli Lilly or Novo

Metsera leads emerging obesity treatments with promising drug MET-233i, showing significant weight loss in trials, amid rising competition.

New Study: Mounjaro Helps Users Drop Over 50 Pounds

Eli Lilly's Mounjaro leads U.S. obesity drug market, outperforming semaglutide in weight loss efficacy and safety.

Novo Nordisk Pushes for First Oral Obesity Drug Approval

Novo Nordisk seeks FDA approval for oral Wegovy, potentially the first oral obesity treatment, amid competition with Eli Lilly.

ProGen’s PG-110 Targets Fat Loss Without Muscle Waste—Next-Gen Obesity Drug in Focus

ProGen will present non-clinical results of its obesity drug PG-110 at the ADA conference, targeting muscle preservation and weight loss.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.